Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MUTAVAC

Financiado

Cerrado

Targeting cancer with mutanome based stem cell vaccine

The successful application of immune checkpoints inhibitors has modified the therapeutic strategies in several cancers but only 30% of patients will respond optimally to these therapies. One of the reasons for the failure of these... ver más

30/09/2024

IPSIRIUS

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

IPSIRIUS No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-30

HORIZON-EIC-2021-PATHFINDERCHALLENGES-01-03: Emerging Technologies in Cell and G... Scope:Cell and gene therapy (CGT) are widely accepted as top biomedical trends for over three years...

I+D

Cerrada hace 3 años

0% 98% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

IPSIRIUS

1.78M€ | Lider

Proyectos interesantes

I-CREATE

Medical Technol...

Biotechnology

5M€ Cerrado

ONCO-VAX

Medical Technol...

Applied Physics

1M€ Cerrado

STI-001

Medical Technol...

Biotechnology

71K€ Cerrado

PROCROP

Medical Technol...

Data Science

8M€ Cerrado

TrojanDC

Medical Technol...

Data Science

75K€ Cerrado

IJC2018-035386-I

Medical Technol...

Immunotherapy

93K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 27 meses Fecha Inicio: 2022-06-17
Fecha Fin: 2024-09-30

Líder del proyecto

IPSIRIUS No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The successful application of immune checkpoints inhibitors has modified the therapeutic strategies in several cancers but only 30% of patients will respond optimally to these therapies. One of the reasons for the failure of these therapies is the resistance of cancer stem cells (CSCs) leading to relapses long after the initial treatment. These cells are also resistant to conventional therapies via their quiescence and there are no targeted therapies available against them. The ambition of IPSIRIUS, a French biotechnology company, spinoff of INSERM and Paris Saclay University is to develop active cancer immunotherapy products based on the revolutionary induced pluripotent stem cell (iPSC) technology. IPSIRIUS developed first IPVAC, with the aim of leveraging patient’s immune system against a large panel of cancer antigens which are shared between iPSC and CSCs. With IPVAC, IPSIRIUS is developing a ground-breaking technology, having resolved all technical issues limiting cell-based therapies used for cancer. IPVAC is a safe, allogenic, off-the-shelf therapy, highly scalable using a versatile technology. This cell-based vaccination strategy showed efficacy in prophylactic and therapeutic settings against aggressive solid cancers with stemness features. The overall goal of the MUTAVAC project is i) to uncover the mechanisms of action of IPVAC, ii) to generate a highly immunogenic version of IPVAC, and iii) to design robust in vitro immunogenicity tests to predict immunogenicity of IPVAC and IPVAC-Mut in humans. With MUTAVAC project, IPSIRIUS will i) strengthen the scientific data on IPVAC to prepare its clinical development and leading to the open access publications and patents, ii) define a personalised medicine to propose efficient therapeutic cancer vaccine in patients with all HLA groups, iii) identify new targets for future cancer therapies, and iv) develop a technological platform to facilitate the development of the next-generation of cell therapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores